Top

13-03-2024 | Short Communication

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research

Authors: Priya Rani, Dua Zehra, Malaika Mansoor, Payal Rani

Published in: Archives of Women's Mental Health

Abstract

Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.

Amgen F (2010) Center for Drug Evaluation and Research Cenobamate Clinical Review. Clin Rev, 0–13

David PS, Smith TL, Nordhues HC, Kling JM (2022) A clinical review on paroxetine and emerging therapies for the treatment of vasomotor symptoms. Int J Women’s Health 14:353–361. https://doi.org/10.2147/IJWH.S282396CrossRef

Depypere H, Lademacher C, Siddiqui E, Fraser GL (2021) Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 30(7):681–694. https://doi.org/10.1080/13543784.2021.1893305CrossRefPubMed

FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause | FDA. (n.d.). Retrieved June 20, (2023) from https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause

Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S (2020) A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause 27(4):382–392. https://doi.org/10.1097/GME.0000000000001510CrossRefPubMedPubMedCentral

Fraser GL, Obermayer-Pietsch B, Laven J, Griesinger G, Pintiaux A, Timmerman D, Fauser BCJM, Lademacher C, Combalbert J, Hoveyda HR, Ramael S (2021) Randomized controlled trial of Neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome. J Clin Endocrinol Metab 106(9):e3519. https://doi.org/10.1210/CLINEM/DGAB320CrossRefPubMedPubMedCentral

Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K (2006) Longitudinal Analysis of the Association between Vasomotor Symptoms and Race/Ethnicity across the Menopausal Transition: study of women’s Health across the Nation. Am J Public Health 96(7):1226–1235. https://doi.org/10.2105/AJPH.2005.066936CrossRefPubMedPubMedCentral

Huang AJ, Cummings SR, Ganz P, Schembri M, Raghunathan H, Vittinghoff E, Gibson CJ, Grady D (2023) Efficacy of continuous Transdermal nitroglycerin for treating hot flashes by inducing nitrate cross-tolerance in Perimenopausal and Postmenopausal women. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2023.1977CrossRefPubMedPubMedCentral

Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N (2023) Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms Associated with Menopause: a phase 3 RCT. J Clin Endocrinol Metabolism. https://doi.org/10.1210/CLINEM/DGAD058CrossRef

Menown SJ, Tello JA (2021) Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review. Adv Therapy 38(10):5025–5045. https://doi.org/10.1007/s12325-021-01900-wCrossRef

Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD (2023) Safety of fezolinetant for vasomotor symptoms Associated with Menopause. Obstet Gynecol 141(4):737–747. https://doi.org/10.1097/AOG.0000000000005114CrossRefPubMedPubMedCentral

Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S (2020) Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause (New York N Y) 27(12):1350. https://doi.org/10.1097/GME.0000000000001621CrossRefPubMed

Title: FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research
Authors: Priya Rani
Dua Zehra
Malaika Mansoor
Payal Rani
Publication date: 13-03-2024
Publisher: Springer Vienna
Published in: Archives of Women's Mental Health
Print ISSN: 1434-1816
Electronic ISSN: 1435-1102
DOI: https://doi.org/10.1007/s00737-024-01456-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content